David Harpole
George Barth Geller Distinguished Professor for Research in Cancer · Duke University Hospital
Credentials: · · · ·
History
Present- Present
- Present
- 1993–1995
- 1991–1993
- 1984–1991
Research
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Nature · 2006 · 1,565 citations
Journal of Clinical Oncology · 2008 · 786 citations
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2023 · 710 citations
97 papers
50 papers · 3 as a fellow
39 papers · 3 as a resident
29 papers · 28 as a resident
29 papers · 1 as a fellow
24 papers · 24 as a resident
22 papers · 22 as a resident
20 papers
Grants
- 2018–2029
Stimulating Access to Research in Residency (StARR) - NIAID
National Institute of Allergy and Infectious Diseases · R38
Contact PI · $2.4M · Duke University
- 2024–2029
Duke Research Training Program in Surgical Oncology
National Cancer Institute · T32
Contact PI · $848.7K · Duke University
- 2018–2028
Stimulating Access to Research in Residency (StARR) - NHLBI
National Heart, Lung, and Blood Institute · R38
Contact PI · $2.6M · Duke University
- 2002–2022
Translational Research in Surgical Oncology
National Cancer Institute · T32
PI · $1.8M · Duke University
Clinical trials
- 2017–2034
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Study chair · Recruiting
VA Office of Research and Development
- 2009–2012
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Study chair · Terminated · Phase 3
Alliance for Clinical Trials in Oncology
- 2004–2011
Study chair · Completed
Alliance for Clinical Trials in Oncology